A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
RAS Mutation Analysis, Thyroid Cancer
Test Code90479
CPT Codes
81275, 81311, 81403, 81276
Includes
HRAS Mutation
KRAS Mutation
NRAS Mutation
KRAS Mutation
NRAS Mutation
Preferred Specimen
Formalin-fixed, paraffin-embedded tissue block
Minimum Volume
Other Acceptable Specimens
Needle washing (see instructions)
Instructions
Do not reject.
Needle washings in alcohol-based fixative (e.g. CytoLyt®) or formalin-fixed, paraffin-embedded tissue block FNA or FFPE specimens are acceptable for the assay.
All specimens must be accompanied with Pathology report. All FFPE specimens will be examined by a pathologist for confirmation and adequacy. Macrodissection if warranted is performed in the lab.
Needle washings in alcohol-based fixative (e.g. CytoLyt®) or formalin-fixed, paraffin-embedded tissue block FNA or FFPE specimens are acceptable for the assay.
All specimens must be accompanied with Pathology report. All FFPE specimens will be examined by a pathologist for confirmation and adequacy. Macrodissection if warranted is performed in the lab.
Transport Temperature
Room temperature
Specimen Stability
FNA or FFPE
Room temperature: 5 years
Refrigerated: 5 years
Frozen: Unacceptable
Needle washings
Room temperature: 30 days
Refrigerated: 30 days
Frozen: Unacceptable
Room temperature: 5 years
Refrigerated: 5 years
Frozen: Unacceptable
Needle washings
Room temperature: 30 days
Refrigerated: 30 days
Frozen: Unacceptable
Methodology
Pyrosequencing
FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
Set up: Daily; Report available: 5 days
Reference Range
HRAS Mutation | Not detected |
KRAS Mutation | Not detected |
NRAS Mutation | Not detected |
Clinical Significance
Activating mutations in the RAS genes, particularly NRAS, have been detected in follicular thyroid carcinomas (up to 40%) and papillary thyroid carcinomas (up to 10%), but are also seen commonly in follicular adenomas. Correlation with morphologic and clinical findings is thus required.
Performing Laboratory
Quest Diagnostics Nichols Institute |
14225 Newbrook Drive |
Chantilly, VA 20153 |